Pfizer, Sanofi record double-digit Q3 sales jumps; Novavax RSV candidate cuts infection by 50% in PhII;

> Pfizer's ($PFE) Q3 vaccines revenue reached $1.14 billion, a 19% increase over the year-ago period. Release (PDF)

> Strong flu vaccine performance and a Pentacel supply recovery drove an 11.2% vaccine revenue increase in Sanofi's ($SNY) third quarter. Release (PDF)

> In a Phase II trial of Novavax's ($NVAX) RSV F-protein vaccine, women who received the vaccine had a 50% reduction in infection. Release

> Germany's ImevaX GmbH, a specialist in vaccines against pathogens of chronic infectious diseases, has wrapped a $9.5 million Series A financing round to develop a vaccine against H. pylori. Release

> Vaccine maker Serum Institute of India says it will invest about $163 million for a new facility in its home country. More

> Israel's BiondVax has won patents in the EU and Japan for its universal flu vaccine. More

And Finally... The global halal vaccine market could be valued at approximately $1.1 billion by 2030 if the market taps into its full consumer base, an expert says. Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

Find out how PDA can help you succeed with custom solutions and training for your employees – at your facility, our facility, or virtually.

Iowa State University is working on a room-temp-stable nasal spray vaccine for COVID-19, and it recently tapped device maker Zeteo for support.

Pfizer's shot will go before an FDA expert panel on Dec. 10, with Moderna's review pegged for the 17th, Warp Speed chief Moncef Slaoui, Ph.D., said.